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ABSTRACT 
Leukocyte recruitment is a universal feature of 
tissue inflammation and regulated by the 
interactions of chemokines with their G protein-
coupled receptors (GPCRs). Activation of CC 
chemokine receptor 2 (CCR2) by its cognate 
chemokine ligands, including CC chemokine 
ligand 2 (CCL2), plays a central role in recruitment 
of monocytes in several inflammatory diseases. In 
this study, we used phosphoproteomics to conduct 
an unbiased characterization of the signaling 
network resulting from CCL2 activation of CCR2. 
Using data-independent acquisition (DIA) MS 
analysis, we quantified both the proteome and 
phosphoproteome in FlpIn-HEK293T cells stably 
expressing CCR2 at six time points after activation 
with CCL2. Differential expression analysis 
identified 699 significantly regulated 
phosphorylation sites on 441 proteins. As expected, 
many of these proteins are known to participate in 
canonical signal transduction pathways and in the 
regulation of actin cytoskeleton dynamics, 
including numerous guanine nucleotide exchange 
factors (GEFs) and GTPase activating proteins 
(GAPs). Moreover, we identified regulated 
phosphorylation sites in numerous proteins that 
function in the nucleus, including several 
constituents of the nuclear pore complex. The 
results of this study provide an unprecedented level 
of detail of CCR2 signaling and identify potential 
targets for regulation of CCR2 function. 
 
 
A universal feature of inflammatory diseases 
is the excessive migration of leukocytes to the 
affected tissues.  Leukocyte recruitment is 
regulated by chemokines, which are secreted at the 
site of injury or infection and then activate 
chemokine receptors, G protein-coupled receptors 
(GPCRs) expressed on the target leukocytes (1-3). 
CCR2 is the major chemokine receptor on 
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monocytes and macrophages, which play key roles 
in numerous inflammatory diseases and also 
express a variety of other chemokine receptors (4). 
The primary cognate ligands of CCR2 are 
considered to be the monocyte chemoattractant 
proteins (CCL2/MCP-1, CCL7/MCP-3 and 
CCL8/MCP-2 as well as CCL13/MCP-4 in humans 
or CCL12/MCP-5 in mice).  
Animal models have consistently shown that 
suppression or inhibition of chemokine receptors 
(or chemokines) ameliorates the symptoms of 
inflammation in disease models. However, 
numerous clinical trials of chemokine receptor 
antagonists have failed, in many cases due to lack 
of efficacy in phase II or III (5,6). Among the many 
factors contributing to the failure of clinical trials, 
one is the complexity of chemokine signaling 
networks (6). For example, most leukocytes express 
multiple chemokine receptors with interconnected 
intracellular signaling networks. Thus, inhibition of 
one receptor could be bypassed by compensatory 
signaling via a different receptor. Consequently, it 
may be advantageous to block certain intracellular 
effectors or pathways, perhaps in combination with 
receptor inhibition to avoid such compensatory 
effects. To identify appropriate targets for such an 
approach, we need a holistic understanding of the 
signaling networks stimulated by chemokine 
receptor activation. 
Genetic deletion of CCR2 or silencing of 
CCL2 protects mice from developing 
atherosclerosis (7-10). Moreover, in a phase II 
clinical trial, inhibition of CCR2, using a 
humanized monoclonal antibody, significantly 
reduced levels of C-reactive protein, an 
atherosclerosis biomarker (11). In type 2 diabetes, 
macrophage infiltration into adipose tissue is 
promoted by activation of CCR2. Thus knockout or 
inhibition of CCR2 in mouse models reduced body 
mass and plasma glucose and restored insulin 
sensitivity (12) and CCR2 blockade lowered 
plasma glucose in type 2 diabetic patients (13). 
More than 15 clinical trials have targeted CCR2 for 
a broad range of indications, (14) although no 
inhibitor has reached the clinic to date.  
In order to gain comprehensive insights into 
signal transduction downstream of CCR2 
activation, we have performed an unbiased 
systems-level phosphoproteomic analysis using 
data-independent acquisition (DIA) mass 
spectrometry, which is the state-of-the-art approach 
to quantify thousands of peptides and proteins with 
superior quantitative accuracy (15-17). 
Specifically, we characterized the global 
phosphoproteome in CCR2-expressing human 
endothelial kidney (HEK293) cells in response to 
an activation time-course with the principal 
endogenous chemokine agonist CCL2. This 
approach represents an advance on traditional 
candidate-based second-messenger assays 
proximal to receptor activation and offered 
opportunities to identify new nodes in the CCR2 
signaling network. Indeed, the extensive signaling 
network identified from the protein 
phosphorylation data included expected chemokine 
receptor signaling pathways, as well as numerous 
additional proteins, pointing to potential novel 
targets related to CCR2 signaling. 
 
Results 
Experimental design to identify the 
phosphorylation events underlying CCR2 
activation 
We have previously generated a CCR2-
expressing cell line (FlpIn-HEK293T-CCR2) to 
investigate chemokine-mediated second messenger 
signaling, including cAMP inhibition, β-arrestin 
recruitment and internalization (18). Building on 
these findings, we sought to characterize the 
signaling networks stimulated by CCR2 activation 
in greater detail using phosphoproteomics. To study 
the kinetics of the underlying phosphorylation 
events, we performed a time course experiment in 
which FlpIn-HEK293T-CCR2 cells were treated 
with the full agonist CCL2 at a concentration (100 
nM) that maximally activates CCR2 (18), for 1.5, 
3, 6, 12, 25 and 60 min prior to harvest. 
Unstimulated FlpIn-HEK293T-CCR2 cells served 
as negative control, and each time point – including 
the 0 min control – was analyzed in biological 
triplicates (Figure 1). The extracted proteins from 
each sample were digested with trypsin and 
phosphopeptides were enriched using TiO2 
chromatography after 10% of the tryptic digest had 
been removed for global proteome analysis. Both 
the enriched phosphopeptides as well as the 
aliquots of tryptic peptides were analyzed and 
quantified by DIA mass spectrometry. In 
comparison to other methods of peptide 
quantification, the DIA approach has improved 
accuracy and reproducibility and is not biased 
towards the most abundant proteins/peptides (19). 
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However, quantification of peptides from DIA data 
must be accomplished by comparison of LC 
retention times and mass spectra with an 
independently established reference library (20). 
To faithfully and accurately evaluate the DIA 
data, we generated comprehensive spectral libraries 
by subjecting a forth replicate of each time point to 
off-line, basic-pH HPLC-C18 fractionation (21). A 
total of 42 fractions (7 time points x 6 fractions) for 
both tryptic peptides and enriched phosphopeptides 
were analyzed by DDA mass spectrometry and the 
results were combined into two distinct libraries 
containing the spectral and chromatographic 
information for 115,093 peptides (derived from 
8,164 proteins) for the analysis of the global 
proteome data and 30,586 phosphopeptides 
(derived from 4,831 proteins) for the analysis of the 
phosphoproteome data. 
 
CCR2 activation induces profound changes in the 
phosphoproteome 
By interrogating our DIA data with these 
comprehensive spectral libraries using Spectronaut 
10 (Biognosys), we were able to obtain quantitative 
information for 7,696 proteins (Table S1) and 
19,931 phosphosites falling below a false discovery 
rate (q-value) cut-off of 1% in at least one of the 21 
samples (7 time points x 3 replicates; Table S2). 
However, to increase the confidence and stringency 
of the phosphoproteomics interpretation, we 
restricted all subsequent analyses to the 11,847 
phosphopeptides that were quantified in at least 15 
of the 21 samples (i.e. for which a maximum of six 
values had to be imputed). The associated 
coefficients of variation (CVs) were observed to be 
around 10% and 25% for the proteome and 
phosphoproteome analysis, respectively, which 
demonstrates high quantitative precision and low 
variability between the biological replicates of each 
time point (Figure S1). 
Differential expression analysis using a one-
way analysis of variance (ANOVA) test revealed 
that the measured levels of 738 phosphosites 
(located on 466 proteins) and 202 proteins showed 
significant changes (i.e. were significantly 
regulated) within 60 min of CCR2 activation by 
CCL2 (adjusted p-value < 0.05; Table S1 and S2). 
Importantly, only 5% of the significantly regulated 
phosphosites are located on proteins whose 
expression levels were observed to change 
confirming that the majority of the observed 
changes in the phosphoproteome are not driven by 
changes in protein expression. Moreover, 
differential expression analyses showed that, in 
comparison to the phosphosites, the expression 
levels of proteins generally did not change until 60 
min after CCL2 treatment, which is in agreement 
with the expectation that alterations in protein 
expression levels are much slower than changes in 
phosphorylation patterns (Figure 2A-F).  
Nevertheless, phosphopeptides on 
significantly regulated proteins were removed from 
further analysis, which reduced the number of 
significantly regulated phosphosites to 699 (located 
on 441 proteins). A principal component analysis 
(PCA) based on these 699 high-confidence 
phosphopeptides (Figure 2G) revealed a time-
dependent clustering pattern, which highlights the 
profound and rapid changes occurring in the 
phosphoproteome even after a short time of CCL2 
exposure (1.5 – 3 min). These changes then 
gradually reversed over time to approach the 
untreated steady-state equilibrium after 60 min. 
 
Gene ontology and pathway enrichment analysis 
To understand the biological pathways and 
signal transduction networks affected by CCR2 
activation, we subjected the 441 proteins that carry 
the 699 significantly regulated phosphosites to 
Gene Ontology (GO) analyses and to enrichment 
analysis of Kyoto Encyclopedia of Genes and 
Genomes (KEGG) pathways, using the Database 
for Annotation, Visualization and Integrated 
Discovery (DAVID) (22) (Table S3). As discussed 
below, these analyses revealed that there is a 
prevalence of regulated protein phosphorylation in 
a number of pathways known to be involved in 
chemokine signaling but also highlighted some 
groups of proteins not usually associated with 
chemokine receptor activation.   
 
Signaling via canonical pathways 
As expected, our set of regulated 
phosphoproteins is enriched for proteins in several 
signal transduction pathways known to be activated 
upon CCR2 (or other chemokine receptor) 
stimulation. These include the mitogen-activated 
protein kinase / extracellular signal-regulated 
kinase (MAPK/ERK) pathway, the 
phosphoinositide 3-kinase / protein kinase B 
(PI3K/AKT) pathway, and the Janus kinase / signal 
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transducer and activator of transcription 
(JAK/STAT) pathway (23-25).  
The enrichment of proteins in these pathways 
provides some internal validation for the accuracy 
of the phosphoproteomics data. However, as a 
means to independently validate our dataset, we 
also sought to detect some of these phosphorylation 
changes using Western blotting, although such 
experiments were limited by the scarcity (and often 
questionable quality) of commercially available 
antibodies recognizing distinct phosphorylation 
sites. One of the hallmarks of chemokine activation 
is the phosphorylation of the two MAPK/ERK 
isoforms (MAPK1 and MAPK3). As shown in 
Figure 3 Western blot data are in excellent 
agreement with the quantitative proteomics (DIA) 
data, both convincingly demonstrating that 
MAPK1 and MAPK3 are rapidly phosphorylated 
upon CCR2 activation, peaking at 1.5-3 min after 
stimulation, then returning to baseline levels by 6-
12 min after stimulation (Figure 3A-D, F). Also, as 
expected, DIA data indicated that phosphorylation 
of c-Jun, a downstream target of MAPK1/3 (26), 
peaks shortly after maximum ERK-1/2 
phosphorylation (Figure 3E). 
As a first step towards validation of our 
observations in monocytes, we have used Western 
blotting to quantify phosphorylation of several 
proteins (MAPK1/3, JUN, STAT3 and RPS6KA1) 
in THP-1 cells, an immortalized monocyte cell line 
that endogenously expresses CCR2. We observed 
good agreement between the time courses of 
phosphorylation in THP-1 cells and the time 
courses observed for the same phosphorylation sites 
in our DIA phosphoproteomics data set (Figure S2). 
 
Phosphorylation of actin- and GTP-related 
proteins 
The regulated phosphoproteome was highly 
enriched in proteins involved in the formation of the 
actin cytoskeleton, cytoskeletal (re)organization, 
and cytoskeleton-related functions such cell 
adhesion or endocytosis (Table S4). Since 
chemokines regulate cell migration and adhesion, 
these observations help to further validate the 
phosphoproteomics dataset. Moreover, the 
reorganization of actin filaments is known to be 
controlled by the Ras family GTPases Rho, Rac and 
Cdc42. Although we did not directly observe 
phosphorylation of these proteins, we found that 
phosphorylation was regulated for a number of 
associated proteins. For example, we observed five 
significantly regulated phosphorylation sites in the 
Ras GTPase-activating protein nGAP (RASAL2), 
all showing similar time courses of early (1.5-6 
min) decreases in phosphorylation before returning 
to baseline (Figure 4A-E). In addition, we observed 
significantly regulated phosphorylation for 
numerous guanine nucleotide exchange factors 
(GEFs) and GTPase activating proteins (GAPs), 
which are positive and negative modulators, 
respectively, of GTPase activity (Figure 4F-J and 
S3). 
 
Phosphorylation of nuclear-related proteins 
In addition to the above effects of chemokine 
receptor activation, we also observed 
phosphorylation (or dephosphorylation) for many 
proteins that exert functions in the nucleus, 
including DNA replication and repair, 
transcriptional regulation, RNA processing, and 
cell cycle regulation. Related to these, the set of 
regulated phosphoproteins was highly enriched in 
components of the nuclear pore complex and other 
proteins involved in nuclear export (Table S4). 
Among these, nuclear pore proteins NUP153 and 
TPR had six and four significantly regulated 
phosphosites, respectively (Figure 5A-E). In 
addition, while some of the regulated nuclear 
proteins underwent relatively fast changes in 
phosphorylation (within ~6 min), others showed 
substantially slower kinetics and/or remained 
significantly different from baseline after 25 or 60 
min (Figure 5 and S4). To our knowledge, the 
regulation of nuclear protein phosphorylation after 
activation of CCR2 (or other chemokine receptors) 
has not been previously studied in detail. Its 
potential significance is discussed below. 
 
A proposed CCL2-CCR2 signaling network 
To provide further insights into the signaling 
pathways resulting from CCR2 activation, we have 
generated a network of interconnected proteins 
whose phosphorylation status changes between any 
of the measured time points (Figure 6). This 
network was assembled in several steps. First, the 
enriched KEGG pathways were connected with 
each other and with known CCR2 proximal 
signaling events. Second, we added regulated 
phosphoproteins that were identified by 
interrogation of the STRING protein-protein 
interaction database to have at least three 
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connections to members of the initial network; 
many of these were also connected to each other. 
Subsequently, the network was manually curated 
and organized to indicate the functional clusters 
discussed above. 
To assist in illustrating the temporal dynamics 
of phosphorylation across this network, we 
classified all 699 regulated phosphosites into three 
groups (fast, medium and slow responders) based 
on the time when the changes reached their 
maximal amplitudes compared to the baseline 
control (coloured circles in Figure 6, Table S2). The 
majority of the phosphosites (74%) reached their 
maximal amplitude within three minutes (fast 
responders), 20% showed maximal changes after 6-
12 min (medium responders), and only a very small 
proportion (7%) reached maximal changes after 25-
60 min. Fast, medium and slow responders were 
fairly evenly distributed throughout the network 
without any apparent spatial-temporal pattern, and 
some proteins even carry multiple phosphosites that 
reach their maximal (de)phosphorylation levels 
after substantially different time periods; examples 
include transcription factor NFκB1, pleiotropic 
Ser/Thr kinase PRKD1, and cell adhesion 
associated kinase EPHA2 (Figure 6). These 
observations accentuate the complexity of the 
CCR2 signal transduction network. 
 
Discussion 
Signaling via pro-inflammatory chemokine 
receptors is critical for the stimulation of leukocyte 
migration in numerous inflammatory diseases. 
However, most studies of chemokine-receptor 
signal transduction have focused on detection of 
well-characterized pathways and effectors (e.g., 
activated G proteins, cAMP levels, phosphorylated 
MAPK1/3, Ca2+ mobilization and β-arrestin 
recruitment) or cellular properties (e.g., chemotaxis 
and proliferation) as readouts for receptor 
activation. A smaller number of studies have 
investigated specific features of the pathways that 
connect receptor activation to cellular outcomes 
(27-30). In this study, to gain new insights into the 
mechanisms of CCR2-activated signal 
transduction, we have taken the unbiased 
phosphoproteomics approach to identify numerous 
phosphorylation (and dephosphorylation) events 
resulting from CCR2 activation. This approach has 
the potential to corroborate prior observations, as 
well as reveal new aspects of the CCR2 signaling 
network. Nonetheless, although the discovery 
proteomics approach used here provides valuable 
insights into the dynamics of CCL2-stimulated 
phosphorylation events, it should be noted that any 
information regarding the sub-cellular localization 
of these signaling events is lacking. This will be an 
area of interest for future investigation. 
We identified nearly 700 phosphopeptides, 
that are significantly regulated in response to CCR2 
activation. In addition to well-known signal 
transduction pathways, our data clearly 
demonstrate that CCR2 activation substantially 
affects actin-, GTP- and nuclear-related proteins. 
Importantly, a significant proportion of these 
identified phosphopeptides have not previously 
been linked to chemokine signaling and some may 
be viable targets to interfere with or disrupt 
chemokine signaling. 
It is noteworthy that we observed 
phosphorylation of the epidermal growth factor 
receptor (EGFR) family member ERBB2 and 
several proteins known to be phosphorylated 
downstream of EGFRs (Figure 6). This is consistent 
with previous reports of crosstalk between 
chemokine receptors and EGFRs (31-34). We 
therefore speculate that such crosstalk also occurs 
for CCR2, although the details are likely to be cell 
type-specific. 
In a previous phosphoproteomic study of 
chemokine signaling in breast cancer stem cells, Yi 
et al. (30) described the effects of the chemokine 
CXCL12 (stromal cell-derived factor-1, SDF-1), 
which activates the receptor CXCR4 to promote 
cancer metastasis. They reported phosphorylation 
changes for numerous kinases and used these to 
construct a putative MAP kinase signaling cascade. 
Despite the differences in the cell types, the 
chemokine-receptor pair and the experimental and 
data analysis methods used, the results of this 
previous study are broadly consistent with the 
observations described herein. Notably, several 
proteins with regulated phosphorylation were 
identified in both studies, including MAP1A and 
MAP1B (involved in regulation of microtubule 
dynamics), A-kinase anchoring proteins (AKAPs; 
involved in chemotaxis), and catenin (involved in 
cell adhesion). Moreover, Yi et al. also reported 
phosphorylation changes for some GEFs and 
NUPs, albeit substantially fewer than observed in 
our data set. The similarities between the findings 
of these studies suggest that the common pathways 
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identified have general significance for mediating 
the responses of diverse cell types to chemokine-
receptor stimulation. 
Our phosphoproteomics data set highlighted 
the involvement of GTP-related proteins in CCR2 
signaling. Several GAPs and GEFs have been 
previously implicated in chemokine signaling. In 
one well-characterized example, stimulation of T 
lymphocytes by the chemokine CXCL12, the 
ligand for CXCR4, induced tyrosine-
phosphorylation of three Rho guanine nucleotide 
exchange factors (ARHGEFs) – SOS1, ARHGEF1 
and DOCK2, giving rise to integrin presentation 
and consequent cell adhesion and arrest (35). In 
another study, CCL2 was found to induce tyrosine 
phosphorylation of p115 RhoGEF (ARHGEF1), 
which was implicated in the migration and 
proliferation of human aortic smooth muscle cells 
in response to CCL2 (27). Although the current 
study did not detect significant regulation of these 
specific factors, it identified a number of additional 
GAPs and GEFs that responded to CCL2 
stimulation (Figure 4 and S3) but have not 
previously been associated with chemokine 
signaling. Importantly, several of these GAPs and 
GEFs are expressed in monocytes, based on 
RNAseq data reported for THP-1 monocytes; (36), 
including ARHGAP21, ARHGAP45, ARHGEF2, 
ARHGEF5, ARHGEF6 and ARHGEF11, 
suggesting that the regulated phosphorylation 
observed here may also occur in cells that 
endogenously express CCR2. Interestingly, the 
majority of the GTPase regulatory proteins 
underwent rapid changes in phosphorylation after 
CCL2 stimulation and remained in their modified 
state until 12 or 25 minutes after stimulation before 
returning to their basal phosphorylation levels. This 
is consistent with the typical time course of 
leukocyte chemotaxis, in which initial responses 
may be detected within approximately 30 minutes 
but continue for several hours (37). 
The current study also revealed 
phosphorylation changes for numerous proteins 
with nuclear-related functions. This is also 
expected, considering that several of the known 
(and observed) signaling pathways regulate the 
activation of transcription factors and that 
chemokine stimulation is known to upregulate 
transcription and protein synthesis, as well as cell 
proliferation (38). Thus, we observed regulated 
phosphorylation of proteins related to 
transcriptional regulation, RNA processing and 
aspects of cell division, such as cell cycle 
regulation, DNA replication or repair and ribosome 
biogenesis. Interestingly, among the 47 proteins 
with regulated phosphorylation that are categorized 
as having nuclear-related functions in our network 
(Figure 6, blue box), to the best of our knowledge 
only one, MKI67, has previously been reported to 
be regulated by chemokine signaling. MKI67 is a 
marker of cell proliferation (39) whose expression 
has been reported to be induced by treatment of 
myoblasts with the CCR2 ligand CCL7 (40). On the 
other hand, two of the identified transcriptional 
regulators, YAP1 and ZEB1, have been reported to 
promote expression of chemokines, including 
CCL2 and CCL8 (41,42), suggesting that they may 
contribute to amplification of chemokine-
stimulated responses through positive feedback 
loops. The identification of so many proteins not 
previously known to be regulated by chemokines 
highlights the level of detail provided by the 
phosphoproteomics approach and its potential to 
yield novel information. 
Among the nuclear-related proteins that were 
particularly prevalent in the CCL2-regulated 
phosphoproteome were proteins involved in the 
nuclear pore complex and nuclear export (Figure 5 
and S4). The nuclear pore complex is comprised of 
seven subcomplexes (Y-Complex, Nup93, Nup62, 
Ndc1, Nup214, Nup98 and Tpr), each consisting of 
proteins with high affinity for each other (43). 
Phosphorylation of nuclear pore complex proteins 
has previously been reported to regulate nuclear 
translocation, the number of nuclear pore 
complexes per nucleus, and nuclear envelope 
reorganization during mitosis (44-47). We 
observed phosphopeptides derived from proteins in 
all but one of the nuclear pore subcomplexes, the 
Nup62 complex, which forms the central pore, and 
significant phosphorylation changes for proteins in 
four subcomplexes. Notably, the significantly 
regulated proteins included all three proteins 
comprising the Tpr complex (Tpr, Nup50 and 
Nup153), which forms the nuclear basket, 
projecting into the nucleoplasm and apparently 
contributing to nuclear organization (48). The 
prevalence of nuclear pore proteins among the 
significantly regulated proteins observed here 
strongly suggests that CCR2 activation gives rise to 
reorganization of the nuclear pore and that this is 
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one mechanism by which chemokine receptor 
activation regulates transcription and translation. 
There is little previous literature regarding the 
influence of chemokine receptor signaling on 
nuclear translocation. In one notable exception, 
Balan and Pal reported that signaling of receptor 
CXCR3-B in breast cancer cell lines increased 
nuclear localization of Bach-1 and increased 
nuclear export of Nrf1 (49). Bach-1 and Nrf-1 
regulate transcription of the anti-apoptotic protein 
heme oxygenase-1 in a positive and negative 
manner, respectively. Thus, the nuclear 
redistribution of these factors resulted in decreased 
expression of heme oxygenase-1 and enhanced 
apoptosis. 
Previous studies have also suggested a more 
direct role of one nuclear pore protein linking 
chemokine signaling to actin dynamics and cell 
migration. Terashima et al. (50) identified a novel 
protein in THP-1 monocytes that associated with 
the intracellular, C-terminal region of CCR2 after 
CCL2 stimulation and was required for CCR2-
dependent activation of PI(3)K/AKT and GTP-Rac, 
leading to actin reorganization and cell migration. 
This protein was named “FROUNT” but was later 
shown to be identical to a component of the nuclear 
pore complex named Nup75 or Nup85 (51,52). The 
same group found that FROUNT also colocalized 
with chemokine receptor CCR5 and with actin after 
chemokine (CCL4) stimulation, promoting 
pseudopodial protrusion towards high chemokine 
concentrations (53). FROUNT was not identified in 
our data set, possibly indicating differences in 
FROUNT expression between HEK293 cells and 
THP-1 cells. Moreover, none of the other nuclear 
pore proteins has significant sequence identity to 
FROUNT, so it seems unlikely that they would 
regulate actin in the same manner. On the other 
hand, we observed four other components of the 
same nuclear pore subcomplex in which FROUNT 
is located (the Y-complex). Among these, Nup133 
and ELYS were significantly regulated and Nup107 
phosphosites also showed kinetic profiles 
suggestive of regulated phosphorylation (Figure 
S4). Thus, it is possible that phosphorylation 
changes of these proteins alter the localization or 
availability of FROUNT for regulation of actin and 
chemotaxis. 
This phosphoproteomics study was performed 
using a stably transfected CCR2 cell-line, which we 
have previously used as a model system to study 
chemokine receptor signaling (18). These receptor-
overexpression systems offer several experimental 
advantages, including uniform expression of the 
transgene (54), which is a distinct advantage for 
proteomics studies as it is likely to reduce 
variability in signaling across the population of 
cells. Moreover, we and others have used HEK293 
cells transfected with CCR2 to investigate nuances 
in chemokine-dependent signaling such as partial 
and biased agonism (18,55). Although these studies 
generally focus on molecular events at or proximal 
to the receptor rather than downstream pathways, 
HEK293 cells transfected with CCR2 have been 
reported to undergo chemotaxis in response to 
CCL2 stimulation (56). Nevertheless, given the 
importance of the CCL2-CCR2 signaling axis in 
monocyte recruitment in the context of 
inflammation, it will be important to follow up the 
current study by phosphoproteomics analyses of 
CCR2 signaling in monocytic cells, which we are 
currently pursuing in our laboratory.  
 
Experimental procedures 
Sample preparation 
The generation of a HEK293 cell line stably 
expressing CCR2 (FlpIn-HEK293T-CCR2) was 
described previously (18). FlpIn-HEK293T-CCR2 
cells were cultured for 16 h in FBS-free DMEM 
medium containing 10 µg/mL tetracycline to 
induce the expression of CCR2 before stimulation 
with 100 nM CCL2 for 1.5 min, 3 min, 6 min, 12 
min, 25 min or 60 min. Untreated cells served as 0 
min control. THP-1 monocytes were cultured in 
RPMI with 10% heat-inactivated FBS 
(ThermoFisher Scientific), and were serum-starved 
for four hours prior to CCL2 stimulation time 
course. After stimulation, cells were washed three 
times with ice-cold PBS and lysed in 1% sodium 
deoxycholate (SDC), 100 mM Tris (pH 8.0) using 
a probe sonicator (Soniprep 150, MSE). The lysate 
was reduced with 10 mM tris(2-
carboxyethyl)phosphine (TCEP; ThermoFisher 
Scientific), alkylated with 40 mM chloroacetamide 
(CAA, Sigma) and the protein concentration was 
determined using the bicinchoninic acid (BCA) 
assay kit (Pierce). A total of four independent 
biological replicates were collected. 
For DIA quantification, 2 mg of protein was 
digested overnight at 37oC with trypsin at a ratio of 
1:100 (w/w, Trypsin Gold, Promega) and SDC was 
removed by extraction with an equal volume of 
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water-saturated ethyl acetate prior to desalting the 
peptides with 30 mg HLB Cartridges (Waters). 10% 
of each sample was directly subjected to LC-
MS/MS for global proteome analysis. The 
remaining 90% was used for phosphopeptide 
enrichment by TiO2 as described previously (57,58) 
followed by LC-MS/MS analysis. 
For the generation of the spectral libraries, 10 
mg of protein was digested overnight at 37oC with 
trypsin at a ratio of 1:100 (w/w, Trypsin Gold, 
Promega). The peptides were fractionated using 
basic pH fractionation as described previously (21). 
A total of 42 fractions were collected and pooled in 
a non-contiguous manner to reduce the number of 
fractions to 6. 10% of each fraction was directly 
analyzed by LC-MS/MS to generate the proteome 
library. The remaining 90% was used for 
phosphopeptide enrichment by TiO2 and analyzed 
by LC-MS/MS to generate the phosphopeptide 
library.  
 
LC-MS/MS 
All samples were analyzed by LC-MS/MS 
using a Q Exactive Plus mass spectrometer 
(ThermoFisher Scientific) coupled online to a 
RSLC nano HPLC (Ultimate 3000, UHPLC 
ThermoFisher Scientific). Samples were loaded 
onto a 100 µm, 2 cm nanoviper Pepmap100 trap 
column, eluted and separated on a RSLC nano 
column 75 µm x 50 cm, Pepmap100 C18 analytical 
column (ThermoFisher Scientific). The tryptic 
peptides or phosphopeptides were separated by 
increasing concentrations of 80% ACN / 0.1% 
formic acid at a flow of 250 nL/min for 150 min.  
Data-dependent acquisition (DDA) mass 
spectrometry was used to analyze the fractions for 
the generation of the spectral libraries. In detail, the 
LC eluent was nebulized and ionized using a nano 
electrospray source (ThermoFisher Scientific) with 
a distal coated fused silica emitter (New Objective). 
The capillary voltage was set at 1.7 kV. The Q 
Exactive mass spectrometer operated in DDA mode 
was set to switch between full MS scans and 
subsequent MS/MS acquisitions. Survey full scan 
MS spectra (m/z 375–1800) were acquired with 
70,000 resolution (at m/z 200) after accumulation 
of ions to a 3 x 106 target value with a maximum 
injection time of 30 ms. Dynamic exclusion was set 
to 20 s. The 10 most intense multiply charged ions 
(z ≥ 2) were sequentially isolated and fragmented in 
the collision cell by higher-energy collisional 
dissociation (HCD) with a fixed injection time of 
60 ms, 17,500 resolution and automatic gain control 
(AGC) target of 5 x 104.  
The following settings were applied to the 
mass spectrometer operated in DIA mode: MS1 
scans were acquired between 370 m/z and 2,000 
m/z with a resolution of 70,000 (at m/z 200) using 
an AGC target of 1 x 106 and a maximum ion 
injection time of 50 ms. Subsequent MS2 scans 
were acquired with a resolution of 17,500 (at m/z 
200) using an AGC target of 2 x 105 with automatic 
injection time control and a loop count of 25. In 
order to minimize the number of co-fragmented 
peptides and phosphopeptides in a given DIA 
window and to increase quantitative precision and 
specificity, we narrowed the DIA isolation 
windows from the conventionally used 25 m/z to 12 
m/z. As a consequence, each sample had to be 
injected 2 or 3 times to consecutively cover a mass 
range of 375 – 975 m/z (for global proteome 
analyses) and 375 – 1275 m/z (for 
phosphoproteome analyses) whilst still adhering to 
a duty cycle of 2 sec (Figure S5).  
 
Data analysis 
MaxQuant and its implemented search engine 
Andromeda (version 1.5.2.8) (59) was used to 
interrogate all DDA files against a human protein 
sequence database, which was downloaded from 
Uniprot/SwissProt in May 2016, containing 20,199 
entries. Cysteine carbamidomethylation was 
specified as a fixed modification, and methionine 
oxidation, N-terminal acetylation and 
phosphorylation at serine, threonine or tyrosine 
were set as variable modifications. Up to 2 missed 
cleavages and a mass tolerance of 20 ppm for the 
first search were permitted. Only proteins and 
peptides falling below a false discovery rate (FDR) 
of 1% were considered for subsequent analyses. 
Spectronaut 10 (Biognosys) was used for both 
the generation of the spectral libraries based on the 
MaxQuant result files and for quantification of the 
acquired DIA files. The parameters for the 
generation of the spectral libraries were kept as 
default. In brief, (i) mass tolerance was set as 
dynamic, (ii) the identification FDR threshold for 
MaxQuant results was set at 1%, (iii) protein 
inference was performed and specific trypsin 
digestion was used, (iv) fragment ions with an 
amino acid length of less than 3 were removed, (v) 
the m/z range was specified between 300 and 1800, 
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(vi) the empirical iRT database was used for iRT 
calibration and (vii) the minimum relative fragment 
intensity was set to 5 and the best number of 
fragments per peptide was set between 3 and 6. 
For quantification of the acquired DIA files, 
the raw files belonging to individual injections of 
the same sample were merged using the HTRMS 
Converter (Biognosys). All parameters for 
phosphopeptide or protein quantification were kept 
as default. In brief, (i) intensity extraction for MS1 
and MS2 was set as maximum and mass tolerance 
was set as dynamic, (ii) retention time extraction 
and calibration were set as dynamic using an 
automatic/non-linear regression, (iii) a mutated 
database was used as decoy, (vi) the Kernel density 
estimator was used for p value estimator, (v) the 
MS2 area and sum precursor quantity was used for 
generating protein quantities, (vi) the Q value was 
used for data filtering, (vii) cross run and global 
normalization strategies were used for intensity 
normalization, and protein inference was set as 
automatic. The normalized protein quantities or 
phosphopeptide intensities were exported for 
further analysis. 
 
Statistical analysis 
The DIA quantification results were analyzed 
using Perseus (60) and the R statistical framework. 
Observations with more than six missing values 
across 21 data points (7 time points and 3 biological 
replicates each) were excluded to maximize data 
quality. Missing values for the remaining data were 
imputed based on random draws from a left-centred 
Gaussian distribution in each sample 1.8 Standard 
deviation away from the mean and a width of 0.3 
(60). A one-way ANOVA test was performed, and 
the p-values were adjusted using the Benjamini-
Hochberg method. An adjusted p-value cut-off of 
less than 0.05 was used to identify significantly 
regulated phosphopeptides or proteins upon CCL2 
treatment.  
For the phosphoproteome data, all 
phosphopeptides with a localization probability of 
less than 0.75 (based on the phosphoproteome 
library created from the MaxQuant search results) 
were removed. In addition, phosphosites were 
excluded if the underlying protein itself has been 
observed to be significantly regulated based on the 
proteome data. Significantly regulated 
phosphopeptides were classified into three groups: 
fast (1.5 min or 3 min), medium (6 min or 12 min) 
and slow (25 min or 60 min) responders based on 
the time when the changes reached their maximal 
amplitude compared to the baseline control. 
 
Network generation 
The list of unique proteins with significantly 
regulated phosphopeptides were submitted to 
DAVID Bioinformatics Database (22) for KEGG 
pathway and gene ontology analyses. The 
significantly enriched pathways (Benjamini-
Hochberg, FDR < 0.05, Table S3) were firstly 
manually examined and curated into a preliminary 
CCL2-dependent phosphoproteomic network using 
Cytoscape (61). The network was further expanded 
based on proteins that fell under broad categories of 
actin/GTPase-related activity and nuclear-related 
biological processes. These additional proteins 
were input into the STRING database (62) to 
investigate protein-protein interactions, and new 
proteins with >3 interactions were added to the 
network. 
 
SDS-PAGE and western blotting 
Proteins were separated by SDS-PAGE (4-
12% Bis-Tris Protein Gels (Life Technologies)) and 
transferred onto PVDF membranes (GE Healthcare 
Life Sciences) using a Mini Trans-Blot Cell system 
(Bio-Rad Laboratories). The membrane was 
washed three times with TBS-T Buffer for 5 min 
and blocked for 1 h at room temperature with 5% 
BSA in TBS-T. The blocked membrane was 
incubated overnight at 4°C with the primary 
antibody followed with a horseradish peroxidase-
conjugated secondary antibody for 1 h at room 
temperature. The PVDF membrane was developed 
with Western Lightning Plus ECL reagent 
(PerkinElmer) and images were captured and 
quantified with a ChemiDoc and ImageLab 
software (Bio-Rad Laboratories). The following 
antibodies were used: rabbit anti-GADPH (2118, 
Cell Signaling Technology (CST)); rabbit anti-
phospho-p44/42 MAPK (ERK1/2) 
(Thr202/Tyr204) (9101, CST); rabbit anti-p44/42 
MAPK (ERK1/2) (9102, CST); mouse anti-Stat3 
(9139, CST); rabbit anti-phospho-Stat3 (Ser727) 
(9134, CST); rabbit anti-c-Jun (9165, CST); rabbit 
anti-phospho-c-Jun (Ser63) (2361, CST); rabbit 
anti-RSK1/RSK2/RSK3 (9355, CST); rabbit anti-
phospho-p90RSK (Thr359) (8753, CST); rabbit 
anti-ATF2 (ab32160, Abcam); rabbit anti-phospho-
ATF2 (Thr71) (ab32019, Abcam); goat anti-mouse 
 by guest on A
pril 2, 2020
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
  Phosphoproteomics of CCR2 Signaling 
 10 
IgG (M8642, Sigma Aldrich) and goat anti-rabbit 
IgG (ab6721, Abcam) as the horseradish 
peroxidase-labeled secondary antibodies. 
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ARHGAP, Rho GTPase-activating protein. 
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CCL2, C-C chemokine ligand type 2; 
DIA, data-independent acquisition; 
DDA, data-dependent acquisition; 
EGFR, epidermal growth factor receptor; 
ERK1/2, extracellular signal-regulated kinase 1/2; 
FDR, false discovery rate 
GAP, GTPase activating proteins; 
GEFs, guanine nucleotide exchange factors; 
GO: gene ontology; 
HPLC, high-performance liquid chromatography; 
MAPK1/3, mitogen-activated protein kinase 1/3 
NUP, nucleoporin; 
TPR, the tetratricopeptide repeat; 
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Figure 1. A schematic overview of (phospho)peptide spectral library generation and quantification 
CCR2-expressing cells were stimulated with CCL2 and protein was extracted at multiple time points for tryptic digestion. For the generation of the 
spectral libraries using data-dependent acquisition mass spectrometry (top half), the peptides were fractionated using basic-pH HPLC and the 
phosphopeptides in each fraction were enriched using TiO2 chromatography after a small aliquot of tryptic peptides had been removed for global 
proteome analysis. For (phospho)peptide quantification by DIA mass spectrometry (bottom half), the phosphopeptides were directly enriched with 
TiO2 beads after a small aliquot of tryptic peptides had been removed for global proteome analysis. The acquired spectral libraries were utilized for 
quantification. 
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Figure 2. CCL2-dependent phosphorylation changes arise rapidly compared to protein level changes.  
(A,B) Volcano plots representing the changes of all quantified phosphopeptides (log2(fold change), x-axis) 
and their statistical significance (-log10(q value), y-axis) at (A) 3 min and (B) 60 min relative to unstimulated 
control (0 min). (C) The quantified phosphopeptides at each time point have been ranked according to their 
log2 fold change (relative to control) and plotted in a decreasing fashion along the x-axis. (D, E) Volcano 
plots representing the changes in protein levels and their statistical significance at (D) 3 min and (E) 60 min 
relative to control. (F) The quantified proteins at each time point have been ranked according to their log2 
fold change (relative to control) and plotted in a decreasing fashion along the x-axis. (G) Principal 
component analysis (PCA) (3 biological repeats for each time point) for the significantly regulated 
phosphopeptides.
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Figure 3. CCL2-dependent MAPK/ERK phosphorylation is quantitatively measured using DIA phosphoproteomics.  
CCL2-dependent changes in phosphorylation relative to unstimulated cells are shown, as a function of treatment time, for: (A) MAPK1 at position 
Tyr-204 (Y204), determined by DIA; (B) MAPK3 at positions Thr-185 and Tyr-187 (T185/Y187) and at Tyr-187 alone (Y187), determined by DIA; 
(C) MAPK1, at position Tyr-202 (Y202) and/or Tyr-204 (Y204), determined by Western blot; and (D) MAPK3, at positions Thr-185 and/or Tyr-
187 (T185/Y187), determined by Western blot. (E) Changes in phosphorylation of JUN at position Ser-63 (S63), determined by DIA. (F) Image of 
a representative Western blot. Molecular weight markers have been cropped out; predicted molecular weights of the proteins are indicated. All data 
points for panels A-E are mean ± SEM from 3 biological replicates.
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Figure 4. CCL2 promotes phosphorylation of guanine nucleotide exchange factors (GEFs) and 
GTPase activating proteins (GAPs). 
Phosphorylation time courses in CCR2-expressing cells for selected GAPs and GEFs, including multiple 
phosphopeptides for Ras GTPase-activating protein nGAP (RASAL2; panels A-E), as well as Rho guanine 
nucleotide exchange factors (ARHGEFs; panels F-H), GAPVD1 (panel I) and SLIT-ROBO Rho GTPase-
activating protein 2 (SRGAP2; panel J). Data represent CCL2-dependent changes in phosphopeptide 
intensity relative to unstimulated cells, mean ± SEM from 3 biological replicates. 
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Figure 5. CCL2 promotes phosphorylation of nuclear-related proteins. 
Phosphorylation time courses in CCR2-expressing cells for selected nuclear pore complex proteins and 
proteins involved in nuclear export. These include multiple phosphosites for nuclear pore complex protein 
NUP153 (panels A-C) and nucleoprotein TPR (panels D and E), as well as individual sites for additional 
nuclear pore complex proteins (F-I) and the mRNA export protein Zinc finger CCCH domain-containing 
protein 11A (ZC3H11A; panel J). Data represent CCL2-dependent changes in phosphopeptide intensity 
relative to unstimulated cells, mean ± SEM from 3 biological replicates. 
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Figure 6. CCL2-CCR2 phosphoproteomic signaling network. 
Proteins with significantly regulated phosphorylation in response to CCL2 stimulation (one-way ANOVA, FDR < 0.05) were manually curated into 
a signaling network. KEGG pathways, indicated by green shaded areas and black lines, include proteins with significantly regulated phosphosites 
(blue boxes), proteins with phosphosites that were observed but not regulated (grey boxes), proteins with no observed phosphosites (white boxes), 
and non-protein components (white ovals). The black solid lines connecting these proteins represent activating (arrow head) or inhibitory (blunt 
head) interactions. Many additional proteins (light purple boxes) that have not been associated with chemokine receptor signaling but have known 
interactions with at least three other proteins in the network, are broadly grouped into actin-related and nuclear-related biological processes (pink 
and blue shaded areas, respectively). Interactions between such proteins and KEGG pathway proteins are shown as red and blue dashed lines. Inter- 
and intramolecular interactions between nuclear-related and actin/GTP-related proteins shown as black dashed lines. Regulated phosphorylation 
events were classified as fast, medium or slow, based on the timing of the maximal phosphorylation response relative to baseline (coloured circles). 
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